Bruke

Brendan Burke

Partner
Boston

I work with innovative companies during their most critical stages – formation, scaling and exit.

Brendan Burke focuses on advising entrepreneurs and emerging growth companies across the full life-cycle – from entity formation, founder’s arrangements, angel and venture capital financings, to long term exit strategies.
 

He also works closely with the investors powering the innovation – venture, angel and growth investors, as well as corporate venture arms and strategics in connection with investments, portfolio company exits, and other strategic initiatives.

Brendan works across industries, however he has significant experience representing life sciences, technology and cannabis companies.

Brendan has been ranked by Best Lawyers, as “One to Watch.”

Education

  • Northeastern University School of Law, J.D., 2013
  • Brown University, B.A., 2007

Bar and Court Admissions

BAR ADMISSIONS
  • Massachusetts 

Experience

PRIVATE PLACEMENTS
  • Satellite Bio, a regenerative medicine company, in raising $110 million in Seed and Series A funding, led by aMoon Growth with participation from prior Seed stage investors
  • Alyone Therapeutics, biotechnology company pioneering next-generation precision central nervous system (CNS) therapies, in closing $23 million in funding from funds affiliated with RTW Investments, LP
  • Ankyra Therapeutics, a developer of biotechnology therapeutics in its $45 million Series B Preferred Stock financing
  • Lucy Therapeutics a biotech company developing new ways to treat neurological disorders in its Series A financing
  • Amagma which specializes in the discovery and development of antibody therapeutics against inflammatory diseases in its $16.4 million Series A deal
MERGERS & ACQUISTIONS
  • Columbia Care, a cultivator, manufacturer and provider of cannabis products, in its acquisition of vertically integrated cannabis company Medicine Man Denver, for upfront consideration of $42 million and a potential additional milestone payment in 2022 if certain performance targets are met
  • Glympse Bio a biotechnology company advancing the way diseases are understood, tracked and treated in its $46.7 million Series B financing.
  • OnShape, creators of the first Software as a Service (SaaS) product development platform that unites robust computer aided design (CAD) with powerful data management and collaboration tools, in signing a definitive agreement to sell the business to global technology company PTC for approximately $470 million
  • Fiera Comox Partners, an independent investment manager providing innovative investment solutions to a wide range of investors through private global investment strategies in private equity and agriculture, in its acquisition of Vermont-based Sweet Tree Holdings 1, LLC (d/b/a The Maple Guild), the world’s largest producer of organic maple syrup and related products
  • The Boston Consulting Group, a global management consulting firm, in its acquisition of assets of world-class digital design lab MAYA Design
  • L2, a business intelligence firm that benchmarks the digital performance of consumer brands, in its acquisition by Gartner (NYSE: IT), an information technology research and advisory company
  • Mill Road Capital, a private investment firm focused on investing in publicly traded micro-cap companies in the US and Canada, in the going private acquisition of Skullcandy (Nasdaq; SKUL), a creator of world-class audio experiences through its Skullcandy and Astro Gaming brands, after a contested process
  • CloudLock, an industry leader in cloud security for multiple platforms, in its $300 million cash acquisition by Cisco Systems
  • Mill Road Capital in its acquisition of Mother’s Market & Kitchen

Publications

  • SEC Radically Revamps Regulation A - Part 1 May 19, 2015

Honors & Involvement

HONORS
  • The Best Lawyers in America: Ones to Watch in Corporate Governance and Compliance Law (2020, 2021)
INVOLVEMENT
  • Boston Bar Association, Member